Novel Peptidomimetic GHRH Agonists Significantly Boost Blood Flow in Ischemic Limbs
Background
Peripheral artery disease (PAD) and its severe manifestation, critical limb ischemia (CLI), are debilitating conditions characterized by inadequate blood flow to the limbs, often leading to chronic pain, non-healing ulcers, and limb amputation. Current therapeutic options, including revascularization procedures, are often insufficient or not applicable to all patients, highlighting a significant unmet medical need. This study addresses the knowledge gap by investigating the potential of long-acting peptidomimetic Growth Hormone-Releasing Hormone (GHRH) agonists to improve tissue perfusion in models of hindlimb ischemia.
Results
Treatment with GHRH-LA1 significantly improved blood flow recovery and reduced tissue damage in ischemic limbs. By day 21, the high-dose GHRH-LA1 group showed a 48% improvement in blood flow recovery compared to only 12% in the vehicle control group (p<0.001). Histological analysis revealed a 2.7-fold increase in capillary density (capillaries per muscle fiber) in the high-dose GHRH-LA1 group compared to controls (p<0.001), indicating robust angiogenesis. Furthermore, the incidence of limb necrosis was reduced by 65% in the high-dose treatment group. > The most significant finding was that GHRH-LA1 treatment led to a 3.5-fold increase in functional limb salvage rates compared to vehicle-treated animals (p<0.001), demonstrating a profound therapeutic effect.
Why It Matters
This study provides compelling evidence that peptidomimetic long-acting GHRH agonists can effectively promote tissue perfusion and reduce limb loss in models of severe ischemia. The observed improvements in blood flow and angiogenesis suggest a novel therapeutic pathway for conditions like critical limb ischemia, where current treatments are often inadequate. This research highlights the potential of GHRH-LA1 as a promising new drug candidate for vascular diseases. These findings could pave the way for the development of innovative pharmacological interventions to prevent amputations and improve quality of life for patients suffering from CLI. Future steps would involve further preclinical optimization and subsequent Phase I human clinical trials to assess safety and efficacy.